Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations - Top-Institutions - MDSpire

Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations

  • By

  • Kerstin Junker

  • Peter Hallscheidt

  • Heiko Wunderlich

  • Arndt Hartmann

  • March 16, 2022

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Radiology
    • Pathology
    • Molecular Oncology

  • #2

    Dana-Farber/Brigham and Women’s Cancer Center
    Dana-Farber/Brigham and Women’s Cancer Center

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Radiology
    • Pathology
    • Genitourinary Oncology

  • #3

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Radiology
    • Pathology
    • Cancer Genomics

  • #4

    German Cancer Research Center (DKFZ)
    German Cancer Research Center (DKFZ)

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Cancer Research
    • Molecular Oncology
    • Radiology
    • Pathology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Radiology
    • Pathology
    • Oncology

Original Source(s)

Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations

  • by Kerstin Junker, Peter Hallscheidt, Heiko Wunderlich, Arndt Hartmann

  • March 16, 2022

Related Content

Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications